Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Growth Hormone Deficiency – Executive Insights – Growth hormone deficiency: Executive Insights (US)

Login to access report north_east
Contact sales account_box

Growth hormone deficiency (GHD) is characterized by slow growth or absence of growth, short stature, and absent or delayed sexual development. Accurately testing for GHD is challenging and often cumbersome. Recombinant human growth hormone (rhGH) has been the mainstay treatment for GHD since 1985. The current landscape for rhGH therapy is very competitive; several products are approved, and only a few agents are in late-phase clinical trials. Each of the products in development aims to improve the frequency of dosing, thereby reducing the burden on patients.

Questions answered

  • What is the prevalence of GHD? How are U.S. GHD patients managed?
  • What are the key areas of unmet need and opportunities in the treatment of GHD?
  • Which therapies are in late-phase development for GHD? What is the potential impact of new launches, and how will these therapies affect future opportunity in the treatment of GHD?
  • What are the key drivers of, and limitations on, the market today and in the future?

Product description

Executive Insights provides indication-specific market intelligence withworld-class epidemiology and keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

Geography: United States

Primary research: Three KOL interviews from March 2023

Key companies covered: Novo Nordisk, Eli Lilly, Roche / Genentech, Pfizer, Sandoz, Merck KGaA, Ferring, Ascendis Pharma, Lumos Pharma

Key drugs covered: Norditropin, Genotropin / Genotropin MiniQuick, Omnitrope, Humatrope, Nutropin, Saizen, Zomacton, Skytrofa, Somapacitan (Sogroya), Somatrogon (Ngenla), Ibutamoren mesylate (LUM 201)

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)
Gout, a form of inflammatory arthritis, arises due to the persistent elevation of serum uric acid (sUA) levels. The condition manifests through sudden and intense gout flares, causing significant…
north_east
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
north_east
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
north_east
Report
Non-Small-Cell Lung Cancer – Geographic Focus: China – China In-Depth – Non-Small-Cell Lung Cancer
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east